CA2172605A1 - Dispositif transdermique renfermant la (e)-2-(p-fluorophenethyl)-3-fluoroallylamine pour le traitement de la maladie d'alzheimer - Google Patents
Dispositif transdermique renfermant la (e)-2-(p-fluorophenethyl)-3-fluoroallylamine pour le traitement de la maladie d'alzheimerInfo
- Publication number
- CA2172605A1 CA2172605A1 CA002172605A CA2172605A CA2172605A1 CA 2172605 A1 CA2172605 A1 CA 2172605A1 CA 002172605 A CA002172605 A CA 002172605A CA 2172605 A CA2172605 A CA 2172605A CA 2172605 A1 CA2172605 A1 CA 2172605A1
- Authority
- CA
- Canada
- Prior art keywords
- fluoroallylamine
- fluorophenethyl
- transdermal device
- disease
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne un procédé de traitement de la maladie d'Alzheimer chez un individu consistant à administrer par voie transdermique audit individu une dose thérapeutiquement efficace de (E)-2-(p-fluorophénéthyle)-3-fluoroallylamine ou d'un de ses sels acceptable pharmaceutiquement. Elle concerne également un dispositif transdermique servant à administrer la (E)-2-(p-fluorophénéthyle)-3-fluoroallylamine ou un de ses sels acceptable pharmaceutiquement.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12719093A | 1993-09-24 | 1993-09-24 | |
US08/127,190 | 1993-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2172605A1 true CA2172605A1 (fr) | 1995-03-30 |
Family
ID=22428772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002172605A Abandoned CA2172605A1 (fr) | 1993-09-24 | 1994-08-23 | Dispositif transdermique renfermant la (e)-2-(p-fluorophenethyl)-3-fluoroallylamine pour le traitement de la maladie d'alzheimer |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0720475A1 (fr) |
JP (1) | JPH09505276A (fr) |
CN (1) | CN1131390A (fr) |
AU (1) | AU684545B2 (fr) |
CA (1) | CA2172605A1 (fr) |
HU (1) | HUT75877A (fr) |
IL (1) | IL111017A0 (fr) |
NO (1) | NO961180L (fr) |
WO (1) | WO1995008325A1 (fr) |
ZA (1) | ZA947262B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100479405B1 (ko) * | 2002-05-24 | 2005-03-30 | 주식회사 싸이제닉 | 신남산 이합체, 그 제조방법 및 퇴행성 뇌질환 치료를위한 그의 용도 |
WO2010033045A1 (fr) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions et procédés pour la prévention ou le traitement d’un dépôt bêta-amyloïde |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4861800A (en) * | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
WO1993024120A1 (fr) * | 1992-05-27 | 1993-12-09 | Merrell Dow Pharmaceuticals Inc. | UTILISATION DE (E)-2-(p-FLUOROPHENETHYLE)-3-FLUOROALLYLAMINE DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER |
-
1994
- 1994-08-23 AU AU76364/94A patent/AU684545B2/en not_active Ceased
- 1994-08-23 WO PCT/US1994/009517 patent/WO1995008325A1/fr not_active Application Discontinuation
- 1994-08-23 HU HU9600725A patent/HUT75877A/hu unknown
- 1994-08-23 EP EP94926566A patent/EP0720475A1/fr not_active Withdrawn
- 1994-08-23 JP JP7509764A patent/JPH09505276A/ja active Pending
- 1994-08-23 CN CN94193473A patent/CN1131390A/zh active Pending
- 1994-08-23 CA CA002172605A patent/CA2172605A1/fr not_active Abandoned
- 1994-09-19 ZA ZA947262A patent/ZA947262B/xx unknown
- 1994-09-21 IL IL11101794A patent/IL111017A0/xx unknown
-
1996
- 1996-03-22 NO NO961180A patent/NO961180L/no unknown
Also Published As
Publication number | Publication date |
---|---|
WO1995008325A1 (fr) | 1995-03-30 |
ZA947262B (en) | 1995-05-23 |
JPH09505276A (ja) | 1997-05-27 |
AU7636494A (en) | 1995-04-10 |
IL111017A0 (en) | 1994-11-28 |
HUT75877A (en) | 1997-05-28 |
EP0720475A1 (fr) | 1996-07-10 |
NO961180D0 (no) | 1996-03-22 |
HU9600725D0 (en) | 1996-05-28 |
NO961180L (no) | 1996-03-22 |
CN1131390A (zh) | 1996-09-18 |
AU684545B2 (en) | 1997-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6312716B1 (en) | Patch and method for transdermal delivery of bupropion base | |
EP2494966B2 (fr) | Composition stable de rasagiline | |
US8501727B2 (en) | Short acting benzothiazepine calcium channel blockers and uses thereof | |
JP2010215643A (ja) | 3,3−ジフェニルプロピルアミンモノエステルの高純度の塩基 | |
ZA200506056B (en) | Formulation and methods for the treatment of thrombocythemia | |
CA1257837A (fr) | Produit pharmaceutique topique | |
TWI742628B (zh) | 一種阿哌沙班透皮釋放系統及其使用方法 | |
US20230255923A1 (en) | Short acting phenylalkylamine calcium channel blockers and uses thereof | |
EP2650019B1 (fr) | Timbre transdermique contenant un antidépresseur noradrénergique et sérotoninergique spécifique | |
EP0642338B1 (fr) | UTILISATION DE (E)-2-(p-FLUOROPHENETHYLE)-3-FLUOROALLYLAMINE DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER | |
AU684545B2 (en) | Transdermal device containing (E)-2-(P-fluorophenethyl)-3-fluoroallylamine for the treatment of Alzheimer's disease | |
US6608080B1 (en) | Morphan derivatives or salts thereof and medicinal compositions containing the same | |
HU212502B (en) | Process for producing pharmaceutical preparative containing n-methyl-2-(3-pyridyl)-tetrahydrothiopyrane-2-carbothioamide-1-oxide applicable for treating insufficiency of coronary arteries | |
EP0315217A2 (fr) | Composition pharmaceutique | |
CA2056621A1 (fr) | Administration intranasale d'indolines 3,3 disubstituees |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20000802 |